Superworth

Kiniksa Pharmaceuticals International PE ratio KNSA

Share price divided by earnings per share over the last twelve months, since 2024.

Today, Oct 23, 2026
79.1×
3-year median
85.3×
Against its 3-year history
37th
percentile: 0 is its lowest day, 100 its highest
3-year range
53.8× to 193×
Peer median
36.9×

Kiniksa Pharmaceuticals International's PE ratio is 79.1× as of Oct 23, 2026: a share price of $76.73 against $0.97 of earnings per share over the last twelve months.

That is below its 3-year median of 85.3×, close to the middle of its last 3 years.

Over that time it ranged from 53.8× in May 2026 to 193× in Jul 2024.

The median for 10 large drugmakers of a similar size is 36.9×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far79.1×53.8×106×
202593.3×82.2×96.0×
2024193×93.9×193×

Against its peers

Companies in Drug Manufacturers - General nearest Kiniksa Pharmaceuticals International's size, closest first, today.

CompanyPE ratio
KNSAKiniksa Pharmaceuticals International79.1×
LGNDLigand Pharmaceuticals32.3×
AMRXAmneal Pharmaceuticals41.6×
ALKSAlkermes plc.115×
TGTXTG Therapeutics19.8×
INDVIndivior Pharmaceuticals12.4×
PTGXProtagonist Therapeutics134×
ARQTArcutis Biotherapeutics142×
CORTCorcept Therapeutics204×
LQDALiquidia30.7×
OGNOrganon17.9×
Peer median36.9×

Where Kiniksa Pharmaceuticals International ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Kiniksa Pharmaceuticals International

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.